Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes in Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, and Pancreatic Ductal Adenocarcinoma

Patients with treatment-refractory metastatic colorectal, pancreatic and ovarian cancers were eligible. Lymphodepleting chemotherapy was followed by infusion of ex vivo expanded tumor-infiltrating lymphocyte, manufactured at MD Anderson Cancer Center with IL-2 and agonistic stimulation of CD3 and 4-1BB.